The Depo-Provera Brain Tumor Link: What the Science Actually Says

Published: March 20, 2026 10 min read

The Depo-Provera brain tumor link is not a theory. It's documented in peer-reviewed journals and acknowledged by the FDA. Women who used Depo-Provera for two or more years have a significantly elevated risk of developing meningioma, a brain tumor that grows on the protective membranes surrounding the brain. Here's what the studies found — and why it matters.

What We Know About the Depo-Provera Brain Tumor Link

Depo-Provera's active ingredient is medroxyprogesterone acetate (MPA), a synthetic hormone from the progestin family. MPA is injected into the muscle or under the skin every 12 to 13 weeks and releases slowly into the bloodstream over that period.

Meningiomas — tumors of the meninges, the protective membranes surrounding the brain and spinal cord — are known to be hormonally sensitive. They grow more frequently in women than men, they can accelerate during pregnancy, and they express receptors for both estrogen and progesterone. That last fact is crucial: meningioma cells actively respond to progesterone-like hormones.

When a synthetic progestin like MPA binds to these receptors repeatedly over years, it may stimulate meningioma cell growth. Multiple independent research groups have now confirmed an association between high-dose, long-term progestin use and elevated meningioma incidence. The research is most robust for high-dose progestins used in contraception and gynecological treatment — and Depo-Provera, delivered at 150mg per injection, is the highest-dose progestin contraceptive widely used in the United States.

Key Studies: The Evidence Trail

The 2023 BMJ Cohort Study (France)

The most significant study for U.S. litigation came from the French national health insurance database (Système National des Données de Santé — SNDS), published in the British Medical Journal in February 2023.

Researchers tracked over 108,000 women diagnosed with meningioma between 2009 and 2018 and compared their progestin medication exposure against a control group. The findings were striking:

• Women who used high-dose progestins (including medroxyprogesterone acetate) had a 5.55 times higher risk of meningioma requiring surgery compared to non-users
• The risk was dose-dependent: longer use and higher doses correlated with greater risk
• The association was strongest for intramuscular MPA — the same delivery method used in Depo-Provera
• Elevated risk was observed at the specific receptor locations where MPA-sensitive meningiomas grow: the skull base, parasagittal, and sphenoid wing locations

This study was peer-reviewed, published in one of the world's most respected medical journals, and covered a massive dataset spanning nearly a decade. It is the primary scientific foundation cited by plaintiffs' attorneys in MDL 3140.

Source: Weill A, et al. "Meningioma and hormonal contraceptives: a national cohort study." BMJ. 2023; 381:e075523.

Earlier European Studies

The BMJ study built on earlier French pharmacovigilance work. In 2018, the French National Agency for Medicines and Health Products Safety (ANSM) identified medroxyprogesterone acetate as a meningioma risk factor and began requiring enhanced labeling in France — six years before the FDA acted in the United States.

A 2019 analysis of the French ANSM database specifically found elevated meningioma incidence in women using injectable MPA at doses consistent with Depo-Provera. This data was submitted to European regulatory agencies and prompted label changes across the European Union well before any U.S. action.

The Nordic Countries Cohort

A 2024 study using population-level data from Nordic countries (known for their comprehensive national health registries) further supported the association. The study found a statistically significant elevation in meningioma incidence in women with high cumulative exposure to progestins, with the strongest signal in injectable formulations at high doses.

U.S. Studies and the FDA Pharmacovigilance Database

The FDA's own Adverse Event Reporting System (FAERS) accumulated reports of meningioma in Depo-Provera users over many years before the agency acted. The FDA cited these reports alongside the European population studies when it issued the August 2024 black box warning. The agency's label language specifically notes that the risk is elevated with cumulative use, particularly at high doses — the exact exposure profile of typical Depo-Provera users.

How MPA May Drive Meningioma Growth

Understanding why Depo-Provera may cause meningiomas requires a look at how the drug works at the cellular level.

Progesterone receptors in meningioma cells. Meningioma cells express progesterone receptors (PR) at high levels — higher than most other brain cell types. When a progestin like MPA binds to these receptors, it triggers gene expression changes that can promote cell division and tumor growth.

MPA's potency compared to natural progesterone. MPA is not the same as the progesterone your body naturally produces. It's a synthetic compound designed to be highly stable in the bloodstream — which makes it a reliable contraceptive but also means it delivers a consistent, long-lasting signal to hormone receptors. Natural progesterone fluctuates. MPA, from an injection that releases over 12 weeks, delivers sustained stimulation.

Dose and duration effects. The biology supports the dose-response relationship seen in the epidemiology. Higher doses mean more receptor stimulation. Longer duration means more cumulative cycles of that stimulation. This maps directly to the research showing that women with more Depo-Provera exposure have proportionally higher meningioma risk.

Tumor location patterns. Meningiomas associated with progestin exposure tend to appear at characteristic locations: the skull base (the sphenoid bone and olfactory groove area) rather than the more common convexity meningiomas seen in older patients. This location-specific pattern is considered a scientific marker of hormonally-driven tumor development — adding biological plausibility to what the epidemiological studies already showed.

How the FDA Responded — And What Took So Long

In August 2024, the FDA updated the Depo-Provera label to include a boxed warning — the strongest safety alert the agency can require. The warning states that high-dose progestin use has been associated with meningioma, and that healthcare providers should consider this risk when prescribing.

The FDA's action in 2024 came years after European regulators had already acted. France required enhanced meningioma warnings starting in 2018. The European Medicines Agency (EMA) had updated its guidance on high-dose progestins and meningioma risk by 2020. The 2023 BMJ study — which covered data through 2018 — was the apparent trigger for the FDA's domestic action.

The gap between when the data existed and when the FDA acted is central to the legal theory in MDL 3140. Plaintiffs allege that Pharmacia & Upjohn (Pfizer) was aware of or should have been aware of European regulatory actions and underlying research, and failed to update U.S. labeling to warn American women of the risk for years.

For more on the FDA's warning and what it means, see: Depo-Provera and Meningioma: What the FDA's 2024 Warning Means for You.

Who Is at Highest Risk?

Based on the available research, the highest-risk profile for Depo-Provera-related meningioma involves:

• Cumulative use of 5 or more years: Risk increases substantially with duration
• Use at 150mg per injection dose (the standard U.S. Depo-Provera dose): Higher risk than lower-dose progestin methods
• Use beginning before age 40: Longer reproductive life ahead means more years of potential tumor development
• Continued use into middle age (40s–50s): Meningiomas are more common with age; progestin stimulation compounds background risk
• No alternative contraceptive risk factors to explain the tumor: Women without other known meningioma risk factors have a cleaner attribution to Depo-Provera

However, shorter-term users (2–5 years) and women who stopped years ago are not automatically excluded. The research shows elevated risk across a range of exposure levels, and meningiomas may not manifest until years after stopping the drug.

What the Depo-Provera Brain Tumor Link Means Legally

The scientific consensus now supporting the Depo-Provera brain tumor link is strong enough that the FDA acted with its most serious safety label. That institutional acknowledgment significantly strengthens the legal claims of women in MDL 3140.

In a product liability lawsuit, plaintiffs must show: (1) the product is unreasonably dangerous, (2) they were not warned of the danger, and (3) the product caused their injury. The 2024 FDA black box warning helps establish points 1 and 2. The published science, including the BMJ study, helps establish point 3.

If you used Depo-Provera for two or more years and have been diagnosed with meningioma, the scientific evidence supports that there may be a causal connection. An attorney can evaluate whether your case meets the legal standards for filing a claim.

For more on the legal process, see:

• Do I Qualify for a Depo-Provera Lawsuit?
• How to File a Depo-Provera Claim
• Depo-Provera Lawsuit 2026 Update